Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays  by Peeters, M. et al.
Genetic diversity among human immunodeﬁciency virus-1 non-B
subtypes in viral load and drug resistance assays
M. Peeters1, A. F. Aghokeng1,2 and E. Delaporte1
1) UMR 145 ‘VIH et Maladies Associe´es’ Institut de Recherche pour le De´veloppement (IRD) and University of Montpellier 1, Montpellier, France and
2) Virology Laboratory IMPM/IRD, Yaounde, Cameroon
Abstract
The tremendous diversity of human immunodeﬁciency virus (HIV)-1 strains circulating worldwide has an important impact on almost all
aspects of the management of this infection, from the identiﬁcation of infected persons, through treatment efﬁcacy and monitoring, and pre-
vention strategies such as vaccine design. The areas where HIV-1 genetic diversity is highest are those where the majority of patients in need
of treatment and biological monitoring live. With increased access to treatment in these areas, it is expected that the demand for monitoring
tools such as viral load assays and resistance tests will also increase, and their reliability will be critical. Regular updates of these assays during
the last two decades have aimed at improving their performances in different ways that include their reliability with different HIV-1 strains.
We here review to what extent HIV-1 genetic diversity still limits or not the use of currently available viral load and resistance tests.
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Introduction
The global human immunodeﬁciency virus (HIV)/AIDS epi-
demic is characterized by high diversity of HIV. On the basis
of phylogenetic analyses of numerous isolates obtained from
diverse geographical sources, HIV is subdivided into types,
groups, subtypes, sub-subtypes, circulating recombinant
forms (CRFs) and unique recombinant forms (URFs) [1]. This
viral diversity has implications for possible differences in dis-
ease progression, responses to antiretroviral therapy (ART)
(including the development of resistance), vaccine develop-
ment and diagnosis [2]. Here, we review selected aspects of
the genetic diversity of HIV, with particular emphasis on
tests to monitor the efﬁciency of ART.
Classiﬁcation and Molecular Epidemiology
of HIV
AIDS is caused by two viruses: HIV-1 and HIV-2. The initial
genetic diversity of HIV is tightly associated with its origin; the
different groups of HIV-1 (M, N, O and P) and HIV-2 (A–H)
are the results of cross-species transmission events from
different primate sources, namely chimpanzees (Pan troglodytes
troglodytes) and gorillas (Gorilla gorilla) in West Central Africa
for HIV-1, and sooty mangabeys (Cercocebus atys) in West
Africa for HIV-2 [3–5]. HIV-1 group M can be further subdi-
vided into nine subtypes (A–D, F–H, J and K), denoted by
letters, and subtypes A and F can be further subdivided into
sub-subtypes, A1–A4, F1 and F2. Numerous intersubtype
recombinant viruses are also observed. When such recombi-
nant viruses spread further within the human population they
become CRFs, and when they remain restricted to a limited
number of individuals they are called URFs. Today, at least 45
CRFs and numerous URFs are recognized (http://www.hiv.
lanl.gov). Fig. 1 illustrates the genetic diversity of HIV-1.
The classiﬁcation of HIV strains has helped in tracking the
course of the HIV pandemic. HIV-2 is restricted to West
Africa, and only two variants, HIV-2 groups A and B, are
represented in the HIV-2 epidemic, the others being docu-
mented in one or few individuals only [6]. HIV-1 group O is
endemic in Cameroon, where it represents about 1% of HIV
infections, and HIV-1 groups N and P have been described in
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a handful of individuals from Cameroon only [7,8] (Vallari
et al., 17th Conference on Retroviruses and Opportunistic
Infections, 2010). Only HIV-1 group M has spread across
Africa and to all the other continents, and the geographical
distribution of the different HIV-1 group M subtypes and
CRFs is heterogeneous [9,10] (Fig. 2). The initial diversiﬁca-
tion of group M may have occurred within or near the Dem-
ocratic Republic of Congo, where the highest diversity of
FIG. 1. Phylogenetic tree of near full-length genome sequences representing the genetic diversity of the human immunodeﬁciency virus (HIV)-1/
SIVcpz/SIVgor lineage. Representative HIV-1 isolates from groups M, O, N and P were used to perform the phylogenetic analysis (neighbour-
joining method). Within group M, subtypes and sub-subtypes are highlighted in black and circulating recombinant forms (CRFs) in grey. Unique
recombinant forms (URFs) are indicated by dotted grey lines. Branch lengths are drawn to scale (the bar indicates 5% divergence).
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FIG. 2. Schematic representation of the geographical distribution of human immunodeﬁciency virus-1 variants worldwide.
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group M strains has been observed and the earliest cases of
HIV-1 infection (1959 and 1960) were documented [11–13].
The epidemic in the different countries of West, East and
southern Africa is probably the result of different founder
effects. In southern Africa, the epidemic is almost exclusively
attributable to subtype C; subtypes A and D predominate in
East Africa, and CRF02-AG in West Africa [14]. The epi-
demic in Asia is characterized by CRF01-AE and subtype B in
the south-east, by subtypes B and C and B/C recombinants
(CRF07 and CRF08) in China, and by subtype C in India
[15]. In South America, subtypes B and F were initially intro-
duced, and many B/F circulating and unique recombinants are
now present [15]. Finally, in North America and Europe,
subtype B predominates, but the number of new infections
with non-B strains is increasing [16–19].
Overall, non-B HIV-1 variants represent more than 90%
of circulating strains globally, with subtype C accounting for
50% of all infections worldwide [9,15]. Subtypes A, B, D and
G have been shown to account for 12%, 10%, 3% and 6%,
respectively, and CRF01-AE and CRF02-AG for 5% of cases
each [9]. Other recombinants have been shown to account
for 8% of infections [9]. With increasing mobility and migra-
tion, HIV-1 variants inevitably intermix in different parts of
the world, and the distribution of different forms of HIV-1 in
the world is thus a dynamic process. The likelihood of gener-
ating new recombinant viruses will increase and mosaic
genomes will become even more complex, as recombination
involving viruses that are already recombinant will occur.
Even distantly related viruses have been shown to recom-
bine; for example, intergroup recombinants between
group O and M HIV-1 strains have been documented in
Cameroon and now also in France [8,20].
Genetic Diversity and Monitoring of HIV
Infection
ART and patient monitoring in areas where non-B HIV-1
variants predominate
Owing to national programmes and the support of a wide
range of international partners, the number of people receiv-
ing ART in resource-limited countries has signiﬁcantly
increased in recent years, most notably in sub-Saharan Africa
and south and south-east Asia, the two areas where more
than 90% of individuals in need of ART reside [21]. In con-
trast to the situation in high-income countries, monitoring of
ART with viral load (VL) and genotypic resistance testing is
not yet widely available, owing to the high costs of these
tests and the corresponding equipment. However, there are
ongoing initiatives to address the lack of HIV-1 RNA moni-
toring and drug resistance testing in resource-limited coun-
tries. The assays developed and used to monitor HIV
infection and treatment efﬁciency are mainly sequence-based,
and are thus subject to sequence variability constraints that
can signiﬁcantly impact on their performance and reliability.
Genetic diversity and HIV diagnosis
Although genetic diversity has a higher impact on molecular
tests, HIV tests initially showed limitations in detecting HIV-1
group O antibodies, and also some group M variants, espe-
cially during the serological window period [22,23]. Consid-
erable efforts have been made to improve the performance
of these assays by the inclusion of HIV-1 group O antigens
or the use of broadly cross-reactive antigens. The simulta-
neous detection of HIV antigens (p24) and anti-HIV antibod-
ies by fourth-generation assays reduced the window period.
Despite these efforts, the performance of certain serological
assays is actually still suboptimal, although reliable HIV testing
is a critical entry point for patients in need of ART [24–27].
Genetic diversity and VL testing
Monitoring VL as a marker of disease progression and treat-
ment efﬁcacy is essential to provide clinicians with valuable
information on which to base treatment decisions. Since 1995,
many nucleic acid assays have been developed for the quantiﬁ-
cation of HIV-1 RNA in plasma. The ﬁrst assays were based on
target ampliﬁcation, such as RT-PCR, nucleic acid sequence-
based ampliﬁcation (NASBA), a signal ampliﬁcation methodol-
ogy termed branched-chain DNA (bDNA), and ligase chain
reaction (LCX) [28,29]. Currently, almost all assays, both com-
mercial and in-house, are based on real-time PCR technologies,
allowing the simultaneous detection of ampliﬁed products [30].
These technologies have considerably improved the post-
ampliﬁcation process and have reduced problems with con-
tamination by reducing the handling of ampliﬁed samples.
Newer real-time technology options are also faster, have lar-
ger dynamic ranges, have higher throughputs, and can be cou-
pled to fully automated extraction steps [30,31]; however,
they are more sensitive to point mutations within the primer/
probe target sequences.
However, all of these assays are based on nucleic acid
ampliﬁcation and hybridization, and the genetic diversity of
HIV-1 is thus a major challenge for the quantiﬁcation of
plasma HIV-1 RNA. Therefore, the early tests, designed for
subtype B, often failed to detect non-B subtypes [32–38].
The new quantitative HIV-1 assays are designed to cope with
increasing molecular diversity of the virus. Most of the
currently used VL assays have been frequently updated to
improve their ability to correctly detect and quantify the
various HIV-1 group M variants, mainly through the design of
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primers and probes that are conserved across subtypes and
CRFs [39]. However, there is currently no single assay capa-
ble of quantifying the whole spectrum of HIV-1 strains circu-
lating worldwide. Signiﬁcant differences continue to be
observed among different tests, because they use different
primer/probe sequences, target different genomic regions or
use slightly different technologies [28]. Thus, the genetic
diversity of HIV continues to pose problems of underquantif-
ication (>1 log10 copies/mL in certain cases) or detection fail-
ure, which have practical implications for clinical
management and detection of treatment failure. Ideally, each
laboratory should initially compare different HIV-1 RNA
tests and choose the assay that performs best with the HIV
variants circulating in the country. It can also be the case
that discrepancies are not related to particular HIV variants;
therefore, if sufﬁcient resources are available, physicians
should also not hesitate to request VL determination to be
performed with two different assays to highlight underesti-
mation, particularly in cases of discrepancy between the VL
and the CD4 count or clinical observations.
Table 1 shows the characteristics of the VL assays cur-
rently used in routine practice. Despite the high degree of
diversity between HIV-1 group M, N and O viruses, some
tests are able to quantify both HIV-1 group M and O
strains, or HIV-1 group M and N strains [40–43]. Because
of the relatively low sequence homology between HIV-1
and HIV-2, the development of a VL assay that is able to
reliably quantify all subtypes of both viruses is virtually
impossible; however, cross-reactivity may occur [40]. More-
over, no commercial assay is available to quantify HIV-2
plasma VL.
Genetic diversity and drug resistance assays
Drug resistance testing can be performed with either pheno-
typic or genotypic assays. Phenotypic analysis determines the
degree to which a drug inhibits replication of the patient’s
virus in vitro, which is expressed as a fold change in 50%
inhibitory concentration (IC50) as compared with a wild-type
reference HIV strain, and most current assays are based on
recombinant virus assay technologies [44–46]. The advanta-
ges of phenotypic testing are the relatively easy interpreta-
tion, quantitative information on the degree of resistance,
the ability to assess interactions among drugs, and the fact
that it does not require an understanding of genotypic corre-
lates with resistance [44]. Also, phenotypic assays are less
subject to sequence variability.
Most genotypic assays detect resistance mutations by
comparing the protease and the reverse transcriptase
sequences of the investigated virus with those of a wild-type
HIV-1 subtype B reference strain. Although phenotypic and
genotypic assays are complementary, genotypic assays are
preferred for routine patient management, because they are
easier to perform, less expensive and less time-consuming
(days vs. weeks) [47,48]. The most frequently used commer-
cial genotyping assays worldwide are the ViroSeq HIV-1
Genotyping System v2.0 (Celera Diagnostics, Alameda, CA,
USA) [49] and the TRUGENE HIV-1 Genotyping Kit for
Drug Resistance (Siemens Healthcare Diagnostics, Deerﬁeld,
IL, USA) [50]. Both tests are based on direct population
sequencing, and generally do not detect mutants that consti-
tute less than 20% of the virus population [51,52]. To over-
come this limitation, new approaches have been developed,
and the most common include the subcloning and sequencing
of HIV-1 clones, ultra-deep sequencing, oligonucleotide liga-
tion assay, mutation-speciﬁc PCR assays, and the LigAmp
assay [53]. However, like standard genotyping assays, all of
these techniques are also sequence-based and therefore sub-
ject to HIV-1 genome variability.
HIV-1 genetic diversity impacts on sequence-based geno-
typic drug resistance assays at several levels, including perfor-
mance and the interpretation of results. Performance is
closely associated with the efﬁcacy of the primers used for
TABLE 1. Molecular viral load assays currently found in routine practice
Assay name Manufacturer Principle
Target in
HIV-1 genome Dynamic range Detected HIV strains Extraction
Cobas Amplicor HIV-1
Monitor v1.5
Roche RT-PCR, endpoint
detection
gag 400–750 000 copies/mL HIV-1 group M (A–G) Manual and
automated
Cobas AmpliPrep-Cobas
TaqMan HIV-1 v2.0
Roche RT-PCR, real-time
detection
LTR + gag 20–1 · 107 copies/mL HIV-1 groups M, N and O Manual and
automated
Abbott RealTime HIV-1 Abbott RT-PCR, real-time
detection
pol 40–1 · 107 copies/mL HIV-1 groups M (A–H),
N and O
Manual and
automated
NucliSENS EasyQ HIV-1 bioMe´rieux NASBA, real-time
detection
gag 100–3 · 106 UI/mL HIV-1 group M (A–K,
CRF01-AE, CRF02-AG,
CRF14-BG, AG-GH,
CRF11-cpx). May detect HIV-2
Manual and
automated
Versant HIV-1 RNA 3.0 Siemens bDNA pol 50–500 000 copies/mL HIV-1 group M (A–G) No extraction
G2 real-time PCR ‘in-house’ ANRS-Biocentric RT-PCR, real-time
detection
LTR Not provided HIV-1 group M (A–H) Manual
HIV, human immunodeﬁciency virus.
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ampliﬁcation and sequencing, which are generally optimized
for HIV-1 subtype B, especially for the commercial assays
[48,54]. Many studies have reported limitations of these con-
ventional assays in correctly amplifying and sequencing non-B
strains; for example, studies evaluating the ViroSeq System
have reported ampliﬁcation failure and failure rates for
sequencing primers on non-B subtypes [55,56]. The initial
version of the TRUGENE HIV-1 genotyping system also
showed clear limitations in generating usable sequences from
non-B strains (A–J) [57,58]. Several ‘in-house’ methods have
been developed for the genotyping of non-B strains, either
for a large spectrum of non-B strains in areas where these
variants predominate, such as Central and West Africa [59],
or for speciﬁc variants that cannot be correctly tested with
commercial assays, as is the case for subtype C in South
Africa and neighbouring countries [56]. However, care
should be taken with ‘in-house’ techniques, as they are not
always well evaluated and validated. Moreover, a recent pub-
lication on contaminated commercial enzymes clearly
showed the risks and limitations of ‘in-house’ approaches,
stressing the need to put in place a good-quality management
system when using these assays [60].
Also, HIV-1 genetic diversity has an impact on the inter-
pretation of the observed mutations as compared with the
subtype B reference strain. Interpretation of genotypic drug
resistance mutations is based on three algorithms (Stanford,
ANRS and Rega) (http://hivdb.stanford.edu), mainly devel-
oped on the basis of clinical and/or virological data obtained
from patients infected with HIV-1 subtype B. As a conse-
quence, these algorithms can produce important discor-
dances when applied to non-B variants [61,62]. They can
misinterpret mutations that are present in non-B variants as
natural polymorphisms [59,63]. In addition, although most
major resistance mutations in subtype B have also been
found in non-B subtypes, few novel mutations in non-B sub-
types have been recognized and they are not always identi-
ﬁed by the genotypic drug resistance algorithms [64].
Despite regular updates and a recent tendency to incorpo-
rate non-B data in the development of these algorithms,
important discordances remain.
Furthermore, the highly sensitive approaches developed to
detect minor viral populations are even more subject to
HIV-1 sequence variability, which is clearly the key limitation
of point mutation assays, as they are subject to both intra-
subtype and intersubtype variability [65]. Indeed, only sub-
type-speciﬁc oligonucleotide probes are able to hybridize to
the targeted codon with high speciﬁcity, and even within the
same HIV-1 subtype the presence of mismatches between
the probes and tested viruses can impact greatly on the
assay performance [66–68].
Conclusions
Two decades of experience in the management of HIV infec-
tion have demonstrated the usefulness of VL and drug resis-
tance testing for the monitoring of ART in patients. Despite
many efforts, HIV-1 genetic variability continues to have a
signiﬁcant impact on the performance and the reliability of
these assays. Although VL assays have been regularly updated
to encompass the genetic diversity for the pandemic HIV-1
group M strains, very few assays can quantify the other HIV-
1 groups, and there is currently no commercial assay for
HIV-2 quantiﬁcation. Commercial genotypic drug resistance
assays are less frequently updated than VL assays, although
they clearly show limitations in correctly amplifying and pro-
viding usable sequences for HIV-1 non-B strains. Moreover,
none of them is applicable to the other HIV-1 groups or
HIV-2. Actually, the only affordable sensitive techniques for
the detection of minor populations are mainly point muta-
tions assays. Their use will probably remain restricted,
because they are difﬁcult to implement in areas with high
HIV-1 genetic diversity. With the increasing number of
patients receiving ART in areas where only non-B variants
predominate and with the increasing number of non-B infec-
tions in the USA and Europe, the demand for VL and drug
resistance tests for non-B strains will increase signiﬁcantly,
and it is thus important that these tests have, as much as
possible, equal performance with all HIV-1 variants.
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